Tumor-penetrating Peptide Conjugated and Doxorubicin Loaded T1-T2 Dual Mode MRI Contrast Agents Nanoparticles for Tumor Theranostics

The conventional chemotherapeutics could not be traced in vivo and provide timely feedback on the clinical effectiveness of drugs. Methods: In this study, a tumor-penetrating peptide RGERPPR (RGE) modified, Gd-DTPA conjugated, and doxorubicin (DOX) loaded Fe3O4@SiO2@mSiO2 nanoparticle drug delivery...

Full description

Saved in:
Bibliographic Details
Published inTheranostics Vol. 8; no. 1; pp. 92 - 108
Main Authors Gao, Lipeng, Yu, Jing, Liu, Yang, Zhou, Jinge, Sun, Lei, Wang, Jing, Zhu, Jianzhong, Peng, Hui, Lu, Weiyue, Yu, Lei, Yan, Zhiqiang, Wang, Yiting
Format Journal Article
LanguageEnglish
Published Sydney Ivyspring International Publisher 01.01.2018
Subjects
Online AccessGet full text
ISSN1838-7640
1838-7640
DOI10.7150/thno.21074

Cover

Loading…
Abstract The conventional chemotherapeutics could not be traced in vivo and provide timely feedback on the clinical effectiveness of drugs. Methods: In this study, a tumor-penetrating peptide RGERPPR (RGE) modified, Gd-DTPA conjugated, and doxorubicin (DOX) loaded Fe3O4@SiO2@mSiO2 nanoparticle drug delivery system (Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs) was prepared for tumor theranostics. Results: The Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs showed a z-average hydrodynamic diameter of about 90 nm, and a pH-sensitive DOX release profile. The 3 T MRI results confirmed the relaxivity of the NPs (r1 = 6.13 mM-1S-1, r2 = 36.89 mM-1S-1). The in vitro cellular uptake and cytotoxicity assays on U87MG cells confirmed that the conjugation of RGERPPR played a significant role in increasing the cellular uptake and cytotoxicity of the NPs. The near-infrared fluorescence in vivo imaging results showed that the NPs could be significantly accumulated in the U87MG tumor tissue, which should result from the mediation of the tumor-penetrating peptide RGERPPR. The MRI results showed that the NPs offered a T1-T2 dual mode contrast imaging effect which would lead to a more precise diagnosis. Compared with unmodified NPs, the RGE-modified NPs showed significantly enhanced MR imaging signal in tumor tissue and antitumor effect, which should also be attributed to the tumor penetrating ability of RGERPPR peptide. Furthermore, the Hematoxylin and Eosin (H&E) staining and TUNEL assay proved that the NPs produced obvious cell apoptosis in tumor tissue. Conclusions: These results indicated that Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs are an effective targeted delivery system for tumor theranostics, and should have a potential value in the personalized treatment of tumor.The conventional chemotherapeutics could not be traced in vivo and provide timely feedback on the clinical effectiveness of drugs. Methods: In this study, a tumor-penetrating peptide RGERPPR (RGE) modified, Gd-DTPA conjugated, and doxorubicin (DOX) loaded Fe3O4@SiO2@mSiO2 nanoparticle drug delivery system (Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs) was prepared for tumor theranostics. Results: The Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs showed a z-average hydrodynamic diameter of about 90 nm, and a pH-sensitive DOX release profile. The 3 T MRI results confirmed the relaxivity of the NPs (r1 = 6.13 mM-1S-1, r2 = 36.89 mM-1S-1). The in vitro cellular uptake and cytotoxicity assays on U87MG cells confirmed that the conjugation of RGERPPR played a significant role in increasing the cellular uptake and cytotoxicity of the NPs. The near-infrared fluorescence in vivo imaging results showed that the NPs could be significantly accumulated in the U87MG tumor tissue, which should result from the mediation of the tumor-penetrating peptide RGERPPR. The MRI results showed that the NPs offered a T1-T2 dual mode contrast imaging effect which would lead to a more precise diagnosis. Compared with unmodified NPs, the RGE-modified NPs showed significantly enhanced MR imaging signal in tumor tissue and antitumor effect, which should also be attributed to the tumor penetrating ability of RGERPPR peptide. Furthermore, the Hematoxylin and Eosin (H&E) staining and TUNEL assay proved that the NPs produced obvious cell apoptosis in tumor tissue. Conclusions: These results indicated that Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs are an effective targeted delivery system for tumor theranostics, and should have a potential value in the personalized treatment of tumor.
AbstractList The conventional chemotherapeutics could not be traced in vivo and provide timely feedback on the clinical effectiveness of drugs. Methods: In this study, a tumor-penetrating peptide RGERPPR (RGE) modified, Gd-DTPA conjugated, and doxorubicin (DOX) loaded Fe3O4@SiO2@mSiO2 nanoparticle drug delivery system (Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs) was prepared for tumor theranostics. Results: The Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs showed a z-average hydrodynamic diameter of about 90 nm, and a pH-sensitive DOX release profile. The 3 T MRI results confirmed the relaxivity of the NPs (r1 = 6.13 mM-1S-1, r2 = 36.89 mM-1S-1). The in vitro cellular uptake and cytotoxicity assays on U87MG cells confirmed that the conjugation of RGERPPR played a significant role in increasing the cellular uptake and cytotoxicity of the NPs. The near-infrared fluorescence in vivo imaging results showed that the NPs could be significantly accumulated in the U87MG tumor tissue, which should result from the mediation of the tumor-penetrating peptide RGERPPR. The MRI results showed that the NPs offered a T1-T2 dual mode contrast imaging effect which would lead to a more precise diagnosis. Compared with unmodified NPs, the RGE-modified NPs showed significantly enhanced MR imaging signal in tumor tissue and antitumor effect, which should also be attributed to the tumor penetrating ability of RGERPPR peptide. Furthermore, the Hematoxylin and Eosin (H&E) staining and TUNEL assay proved that the NPs produced obvious cell apoptosis in tumor tissue. Conclusions: These results indicated that Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs are an effective targeted delivery system for tumor theranostics, and should have a potential value in the personalized treatment of tumor.The conventional chemotherapeutics could not be traced in vivo and provide timely feedback on the clinical effectiveness of drugs. Methods: In this study, a tumor-penetrating peptide RGERPPR (RGE) modified, Gd-DTPA conjugated, and doxorubicin (DOX) loaded Fe3O4@SiO2@mSiO2 nanoparticle drug delivery system (Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs) was prepared for tumor theranostics. Results: The Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs showed a z-average hydrodynamic diameter of about 90 nm, and a pH-sensitive DOX release profile. The 3 T MRI results confirmed the relaxivity of the NPs (r1 = 6.13 mM-1S-1, r2 = 36.89 mM-1S-1). The in vitro cellular uptake and cytotoxicity assays on U87MG cells confirmed that the conjugation of RGERPPR played a significant role in increasing the cellular uptake and cytotoxicity of the NPs. The near-infrared fluorescence in vivo imaging results showed that the NPs could be significantly accumulated in the U87MG tumor tissue, which should result from the mediation of the tumor-penetrating peptide RGERPPR. The MRI results showed that the NPs offered a T1-T2 dual mode contrast imaging effect which would lead to a more precise diagnosis. Compared with unmodified NPs, the RGE-modified NPs showed significantly enhanced MR imaging signal in tumor tissue and antitumor effect, which should also be attributed to the tumor penetrating ability of RGERPPR peptide. Furthermore, the Hematoxylin and Eosin (H&E) staining and TUNEL assay proved that the NPs produced obvious cell apoptosis in tumor tissue. Conclusions: These results indicated that Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs are an effective targeted delivery system for tumor theranostics, and should have a potential value in the personalized treatment of tumor.
The conventional chemotherapeutics could not be traced in vivo and provide timely feedback on the clinical effectiveness of drugs. Methods: In this study, a tumor-penetrating peptide RGERPPR (RGE) modified, Gd-DTPA conjugated, and doxorubicin (DOX) loaded Fe 3 O 4 @SiO 2 @mSiO 2 nanoparticle drug delivery system (Fe 3 O 4 @SiO 2 @mSiO 2 /DOX-(Gd-DTPA)-PEG-RGE NPs) was prepared for tumor theranostics. Results: The Fe 3 O 4 @SiO 2 @mSiO 2 /DOX-(Gd-DTPA)-PEG-RGE NPs showed a z-average hydrodynamic diameter of about 90 nm, and a pH-sensitive DOX release profile. The 3 T MRI results confirmed the relaxivity of the NPs (r 1 = 6.13 mM -1 S -1 , r 2 = 36.89 mM -1 S -1 ). The in vitro cellular uptake and cytotoxicity assays on U87MG cells confirmed that the conjugation of RGERPPR played a significant role in increasing the cellular uptake and cytotoxicity of the NPs. The near-infrared fluorescence in vivo imaging results showed that the NPs could be significantly accumulated in the U87MG tumor tissue, which should result from the mediation of the tumor-penetrating peptide RGERPPR. The MRI results showed that the NPs offered a T 1 -T 2 dual mode contrast imaging effect which would lead to a more precise diagnosis. Compared with unmodified NPs, the RGE-modified NPs showed significantly enhanced MR imaging signal in tumor tissue and antitumor effect, which should also be attributed to the tumor penetrating ability of RGERPPR peptide. Furthermore, the Hematoxylin and Eosin (H&E) staining and TUNEL assay proved that the NPs produced obvious cell apoptosis in tumor tissue. Conclusions: These results indicated that Fe 3 O 4 @SiO 2 @mSiO 2 /DOX-(Gd-DTPA)-PEG-RGE NPs are an effective targeted delivery system for tumor theranostics, and should have a potential value in the personalized treatment of tumor.
Author Gao, Lipeng
Wang, Yiting
Yu, Jing
Zhou, Jinge
Yan, Zhiqiang
Liu, Yang
Sun, Lei
Wang, Jing
Zhu, Jianzhong
Yu, Lei
Lu, Weiyue
Peng, Hui
AuthorAffiliation 3 Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Fudan University, Ministry of Education, Shanghai 201203, China
1 Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China
2 Key Laboratory of Polar Materials and Devices, Ministry of Education, School of Information Science and Technology, East China Normal University, Shanghai 200241, China
AuthorAffiliation_xml – name: 2 Key Laboratory of Polar Materials and Devices, Ministry of Education, School of Information Science and Technology, East China Normal University, Shanghai 200241, China
– name: 1 Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China
– name: 3 Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Fudan University, Ministry of Education, Shanghai 201203, China
Author_xml – sequence: 1
  givenname: Lipeng
  surname: Gao
  fullname: Gao, Lipeng
– sequence: 2
  givenname: Jing
  surname: Yu
  fullname: Yu, Jing
– sequence: 3
  givenname: Yang
  surname: Liu
  fullname: Liu, Yang
– sequence: 4
  givenname: Jinge
  surname: Zhou
  fullname: Zhou, Jinge
– sequence: 5
  givenname: Lei
  surname: Sun
  fullname: Sun, Lei
– sequence: 6
  givenname: Jing
  surname: Wang
  fullname: Wang, Jing
– sequence: 7
  givenname: Jianzhong
  surname: Zhu
  fullname: Zhu, Jianzhong
– sequence: 8
  givenname: Hui
  surname: Peng
  fullname: Peng, Hui
– sequence: 9
  givenname: Weiyue
  surname: Lu
  fullname: Lu, Weiyue
– sequence: 10
  givenname: Lei
  surname: Yu
  fullname: Yu, Lei
– sequence: 11
  givenname: Zhiqiang
  surname: Yan
  fullname: Yan, Zhiqiang
– sequence: 12
  givenname: Yiting
  surname: Wang
  fullname: Wang, Yiting
BookMark eNpVjk1P3DAQhq0KVJYtl_4CH7mE-jOOL5XQLrRIuwWh9Bx548muV1k72A6id3444eNA5zKjefQ-M6foyAcPCH2n5EJRSX7knQ8XjBIlvqAZrXhVqFKQo0_zCTpLaU-mEoRpqr-iE6aZJkrLGXqux0OIxQAecjTZ-S2-gyE7C3gR_H7cmgwWG2_xMjyFOG5c6zxeBWOndU2LmuHlaHq8DlNifX_zmppEKePLLfic8B_jw2Bidm0PCXch4reLuN5BnFCaQPqGjjvTJzj76HP09_qqXvwuVre_bhaXq2LPhcyFpVJxUyrodKV4Z0CXstTtRpaiolBWTFmz6VhrK2s0VKQjHWhqudCWCqIJn6Of795h3BzAtvD6at8M0R1M_NcE45r_iXe7ZhseG6kEFyWbBOcfghgeRki5ObjUQt8bD2FMDdUVZ1JqQfkLZXaAqA
ContentType Journal Article
Copyright Ivyspring International Publisher 2018
Copyright_xml – notice: Ivyspring International Publisher 2018
DBID 7X8
5PM
DOI 10.7150/thno.21074
DatabaseName MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

DeliveryMethod fulltext_linktorsrc
Discipline Engineering
EISSN 1838-7640
EndPage 108
ExternalDocumentID PMC5743462
GroupedDBID ---
53G
5VS
7X8
ADBBV
ADRAZ
AENEX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
DIK
GROUPED_DOAJ
HYE
KQ8
M48
M~E
O5R
O5S
OK1
PGMZT
RPM
5PM
ID FETCH-LOGICAL-j345t-d1573a67ef9873fae96569cb56481e6827dabf2cd8da9e80f0fe91d349d140903
IEDL.DBID M48
ISSN 1838-7640
IngestDate Thu Aug 21 14:12:22 EDT 2025
Fri Jul 11 12:27:18 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-j345t-d1573a67ef9873fae96569cb56481e6827dabf2cd8da9e80f0fe91d349d140903
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: The authors have declared that no competing interest exists.
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.7150/thno.21074
PMID 29290795
PQID 1983255941
PQPubID 23479
PageCount 17
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5743462
proquest_miscellaneous_1983255941
PublicationCentury 2000
PublicationDate 20180101
PublicationDateYYYYMMDD 2018-01-01
PublicationDate_xml – month: 01
  year: 2018
  text: 20180101
  day: 01
PublicationDecade 2010
PublicationPlace Sydney
PublicationPlace_xml – name: Sydney
PublicationTitle Theranostics
PublicationYear 2018
Publisher Ivyspring International Publisher
Publisher_xml – name: Ivyspring International Publisher
SSID ssj0000402919
Score 2.450343
Snippet The conventional chemotherapeutics could not be traced in vivo and provide timely feedback on the clinical effectiveness of drugs. Methods: In this study, a...
The conventional chemotherapeutics could not be traced in vivo and provide timely feedback on the clinical effectiveness of drugs. Methods: In this study, a...
SourceID pubmedcentral
proquest
SourceType Open Access Repository
Aggregation Database
StartPage 92
SubjectTerms Research Paper
Title Tumor-penetrating Peptide Conjugated and Doxorubicin Loaded T1-T2 Dual Mode MRI Contrast Agents Nanoparticles for Tumor Theranostics
URI https://www.proquest.com/docview/1983255941
https://pubmed.ncbi.nlm.nih.gov/PMC5743462
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT8QgECY-LnowPuM7mHhlXVpa4GSMj6hxjTHdxNsGCviIgu62id794Q7dmrjGg9c2DGQY4Jth-AahfaukcZlwBGxXEjAKSnSZKGI1YBPrKE_L-FC4d52f99nlXXY3hb7rd7YKHP3p2sV6Uv3hc-f97eMQFjzg1w4HPHNQPfjQSWJm4TSahROJxwXaa2F-syODkySbGh9gwAKGxbpjptJfzSdQ5mSO5I9D52wRLbRoER-Np3cJTVm_jOZ_cAiuoM-ifglDAoO2DQOuv8c3MVPFWHwc_FMdw2QGK2_wSXgPw1rHq3R8FZSBzwUlRYJPaugjFkXDvduL2AoEjSp8FF9djTDsv-BYt_lzGDAubnrERXy55UPD87yK-menxfE5aUsrkKeUZRUxNOOpyrl1UvDUKSsB18lSZzkT1OYi4UZpl5RGGCWt6Lqus5KalEkTGbK66Rqa8cHbdYSpkCBFCyadZFmZanCAlEwcCGIZ18kG2vtW6gBMN95HKG9DPRpQCdsJeDSMbiA-oe3B65hqYxDJryf_-MeHhgQ7A-jD8mTzH9K30BzAHDEOnGyjmWpY2x2AEpXebexkt4nxfAHBLc3l
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tumor-penetrating+Peptide+Conjugated+and+Doxorubicin+Loaded+T1-T2+Dual+Mode+MRI+Contrast+Agents+Nanoparticles+for+Tumor+Theranostics&rft.jtitle=Theranostics&rft.au=Gao%2C+Lipeng&rft.au=Yu%2C+Jing&rft.au=Liu%2C+Yang&rft.au=Zhou%2C+Jinge&rft.date=2018-01-01&rft.issn=1838-7640&rft.eissn=1838-7640&rft.volume=8&rft.issue=1&rft.spage=92&rft_id=info:doi/10.7150%2Fthno.21074&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1838-7640&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1838-7640&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1838-7640&client=summon